A：Shanghai Health Care Pharmaceutical was established in December 2019 and currently operates in Baoshan District, Shanghai. The company has developed rapidly in the past few years. It successfully listed in Hong Kong in December last year and completed three rounds of ABC's cumulative 1.5 billion RMB financing, including 1 billion Hong Kong dollars of listing financing, ensuring the safety and stability of the company's capital situation.

A：Chairman Liu Yanjun is a veteran of the industry, with 30 years of experience in the pharmaceutical industry and clinical experience. He was the head of Shanghai Fudan Zhangjiang R & D, the dean of Shanghai Pharmaceutical Research Institute and the vice president of Shanghai Pharmaceutical R & D. He founded Shanghai Baoji Pharmaceutical in 19 years after leaving Shangyao, and successfully led the team to create a highly competitive product pipeline. General Manager Wang Zheng has more than 20 years of experience in the field of recombinant protein drug research and development, established a strong technical barriers and technology platform, and successfully led the team to promote a number of front-end projects.

A：The company's product pipeline focuses on four strategic therapeutic areas, the market size of more than 50 billion, has formed three core technology platforms-drug design, biological manufacturing and chassis cell transformation. At present, the company has a number of pipelines into the clinical stage, and two products have been approved for listing, research and development efficiency and certainty are better than the same stage listed in Hong Kong companies. Up to now, the company's R & D team in Shanghai and Suzhou has more than 350 people, more than 70% of whom are R & D personnel, laying a solid foundation for the promotion of pipelines.

A：The company has two industrialization bases in Baoshan District, Shanghai, and the Xichang plant will be purchased through assets and put into full use in 2021, mainly for the commercial production of long-acting follicle-stimulating hormone and recombinant human hyaluronidase. The Dongchang plant is newly built by the company with the support of the local government. It is expected to be fully put into use in September this year. It will be used for the subsequent large-scale preparation of products such as recombinant chymotrypsin and recombinant ustastatin. Commercial production and clinical sample production. Through limited funds to achieve research and development progress and production base landing, thus laying a cost-leading advantage.

A：The company relies on three major technology platforms (drug design platform, chassis cell building platform and complete manufacturing platform) to drive the development of all product pipelines. Under the mammalian cell platform, long-acting follicle-stimulating hormone and recombinant hyaluronidase have been successfully approved for listing, both of which have been supported by major national new drug projects. The KJ101 recombinant human chymotrypsin project under the yeast cell platform can produce tens of tons of chymotrypsin annually in the future, and has received support and corresponding government subsidies from the Shanghai Economic and Information Commission for tackling key technical problems in key areas of industrial strategy.

A：The iQiyi degradation enzyme product pipeline under the E. coli platform has made a major breakthrough, we have the world's first low-immunogenicity recombinant IT degradation enzyme product line, and has been for a number of indications issued by the State Food and Drug Administration breakthrough therapy recognition. At present, the product has completed the priority review publicity, is in the process of applying for marketing approval, the approval process will be accelerated by the priority review. This product has also been supported by the Shanghai Municipal Science and Technology Commission Science and Technology Innovation Action Plan Fund.

A：The product pipeline has been reported for marketing approval and has been given priority review and publicity for desensitization treatment before renal transplantation. At the same time, the clinical trials of anti-GBMB and GBS are also progressing rapidly, in the second and third phase. In addition, in overseas and domestic phase I clinical trials, the safety advantages of the product are obvious, especially in the rapid reduction of ige levels in the body, which can provide a safe and effective treatment cycle within a week. The new plant has laid out a series of product pipelines in the field of synthetic biology, such as recombinant chymotrypsin and recombinant ulinastatin. At present, these two products on the market are mainly derived from biochemical extraction, and there are problems such as safety, raw material supply and high production cost. However, through synthetic biology technology, we have successfully shortened the fermentation cycle to three days and achieved an annual output of 0.1 billion, greatly improving production efficiency and reducing costs, making the product pipeline of recombinant chymotrypsin and recombinant ulinastatin fast, safe and low-cost.

A：In the desensitization experiment before renal transplantation, the second-stage clinical results showed that the success rate of desensitization within 24 hours after administration was 100. No antibody-mediated rejection occurred 6 to 12 months after transplantation, and the survival rate of transplant recipients and grafts was 100. This indicates that IG degradation enzyme has extremely high therapeutic value for patients who are in urgent need of kidney transplantation but are blocked by high ige antibody levels, and the clinical enrollment is smooth, laying the foundation for subsequent commercialization.

A：The pipeline of anti-GBM therapeutic products is under development. Compared with existing treatment methods, our products can quickly relieve the disease onset, reduce tissue damage, and are expected to be combined with immunotherapy to expand the market potential. In addition, we are promoting the combined use of IG degradation enzymes and anti-enzyme recombinant antibodies in order to provide more effective treatments for various immune diseases. The combined product pipeline of Kang CD20 and KJ103 is expected to submit an application for clinical approval to the State Drug Administration this year.

A：We are advancing the clinical phase II trial of recombinant chymotrypsin and plan to move rapidly into clinical phase III. At the same time, the investment of the industrialization base will simultaneously promote the commercial large-scale production. In addition, the market price of biochemical extraction products is increasing year by year, and with the large-scale production of the health care pharmaceutical industry, the output is not limited, laying the foundation for future commercial development.

A：Recombinant ulinastatin has applied for clinical approval and has been accepted. After receiving the approval, we will immediately start the promotion of clinical progress. These two types of products are expected to generate stable and substantial revenues after launch, providing cash flow support for the continued development of the healthcare pharmaceutical industry.

A：Recombinant human hyaluronidase was approved for listing on March 31 this year and will promote commercial sales and production. In addition, we have cooperated with a number of domestic antibody companies and well-known CDMO companies, especially Yao Ming Bio. Through the cooperation of technology transfer and technology mode, we have ensured that the technology transfer effect in China is good, and the hyaluronidase has been exported to overseas markets. In the future, with the experience of pharmaceutical biology, it is expected to successfully transfer technology to overseas plants in domestic plants.

A：An overseas Nasdaq-listed company called hello, which focuses on subcutaneous drug delivery platforms, has a market value of US $8.4 billion on May 12, 2026. By partnering with big MNCs with strong payment capabilities, such as Johnson & Johnson, the company's revenue and market capitalization have been significantly reflected. Although the health care pharmaceutical industry is a latecomer, we are looking forward to domestic and foreign partners through stable supply and quality control.

A：South Korea's competing LT gen has a large pipeline of products, but its market value valuation of hyaluronidase has also been positively enhanced through partnerships with companies such as Moshadong and Daiichi Republic and AstraZeneca. As hyaluronidase came to market and partnered, its value soared.

A：Recombinant human hyaluronidase can convert a large volume of liquid that originally required intravenous administration into subcutaneous administration, significantly shorten the administration time, and the effect is not significantly different from intravenous administration. Through the cooperation with Yao Ming Bio, we are developing a series of two anti-field and antibiotic subcutaneous preparations, and have entered the clinical phase I. This is expected to change the current way of antibiotic administration from intravenous to subcutaneous injection, which greatly facilitates the patient's medication experience and ensures the continuous level and safety of the drug.

A：We have developed an innovative subcutaneous formulation of bispecific anti-HER2 antibody and the product is in Phase I clinical phase. In addition, we have made progress in the field of hyaluronidase with many partners, and will inform you of the relevant situation in time after the release of the first phase of clinical data.

A：Long-acting follicle-stimulating hormone is one of the product pipelines that we obtained marketing approval in August last year. We sold it as a national CSO by entrusting Anke Biology. Compared with the tedious process of traditional daily injection of short-acting follicle-stimulating hormone, which requires 7 to 10 injections, long-acting follicle-stimulating hormone is designed to replace the usage of seven days with one injection, which greatly improves the convenience and patient experience, especially for most women who need assisted reproductive means.

A：Since its listing, Baoji Pharmaceutical has made a number of important progress in the timeline of 2023. Including recombinant IG degradation enzyme anti-GBMB3 clinical launch, antibody subcutaneous preparation completed a phase of clinical trials, recombinant human hyaluronidase to get a listing license, etc., and the company's shares were also included in the Hong Kong Stock Exchange list. At the same time, the company has also obtained clinical approvals and priority review approvals for a number of products, such as new indication clinical trial approvals for recombinant Ustatins and recombinant human chymotrypsin, and expects to submit NDA listing applications in the first half of the year.

A：Although the company will face a loss in 2023, this is mainly to increase investment in research and development to accelerate the clinical advancement of the research and development product pipeline. The company is expected to break even or even make a profit in or after 2028 as several key product pipelines go to market and achieve large-scale sales revenue. At present, the company's capital safety factor and operation are in good condition, and the construction of industrialization base has been completed and put into production, which will effectively guarantee the future cash flow. At the same time, the advantages of its own industrialization base were reflected during the epidemic, ensuring the smooth production of clinical samples.